secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001104659-23-079774
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 8.01, 3.02, 3.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical acquires Evoqua hemodialysis concentrates business for $16M total consideration
--------------------------------------------------------------------------------

- Acquisition for $11M cash at closing plus two $2.5M installments at 12 and 24 months.
- Funded from cash; post-close cash was $15.3M.
- Acquired business generated ~$18M trailing revenue and >$3.3M EBITDA.
- 2023 revenue guidance raised to $82-86M from prior expectation.
- Preliminary Q2 2023 revenue $18.0-18.3M, net loss per share pro forma $(1.31) for FY 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000110465923079774/0001104659-23-079774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000110465923079774/tm2320979d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-079774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer